141 related articles for article (PubMed ID: 14556270)
1. Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge.
Sajic D; Ashkar AA; Patrick AJ; McCluskie MJ; Davis HL; Levine KL; Holl R; Rosenthal KL
J Med Virol; 2003 Dec; 71(4):561-8. PubMed ID: 14556270
[TBL] [Abstract][Full Text] [Related]
2. NK and NKT cell-independent contribution of interleukin-15 to innate protection against mucosal viral infection.
Gill N; Rosenthal KL; Ashkar AA
J Virol; 2005 Apr; 79(7):4470-8. PubMed ID: 15767447
[TBL] [Abstract][Full Text] [Related]
3. Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2.
Kwant A; Rosenthal KL
Vaccine; 2004 Aug; 22(23-24):3098-104. PubMed ID: 15297061
[TBL] [Abstract][Full Text] [Related]
4. Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod (R-848).
McCluskie MJ; Cartier JL; Patrick AJ; Sajic D; Weeratna RD; Rosenthal KL; Davis HL
Antiviral Res; 2006 Feb; 69(2):77-85. PubMed ID: 16377001
[TBL] [Abstract][Full Text] [Related]
5. Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with beta interferon production.
Gill N; Deacon PM; Lichty B; Mossman KL; Ashkar AA
J Virol; 2006 Oct; 80(20):9943-50. PubMed ID: 17005672
[TBL] [Abstract][Full Text] [Related]
6. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract.
Gallichan WS; Woolstencroft RN; Guarasci T; McCluskie MJ; Davis HL; Rosenthal KL
J Immunol; 2001 Mar; 166(5):3451-7. PubMed ID: 11207303
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA.
Ashkar AA; Yao XD; Gill N; Sajic D; Patrick AJ; Rosenthal KL
J Infect Dis; 2004 Nov; 190(10):1841-9. PubMed ID: 15499542
[TBL] [Abstract][Full Text] [Related]
8. Importance of myeloid differentiation factor 88 in innate and acquired immune protection against genital herpes infection in mice.
Tengvall S; Harandi AM
J Reprod Immunol; 2008 Jun; 78(1):49-57. PubMed ID: 17945349
[TBL] [Abstract][Full Text] [Related]
9. A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection.
Harandi AM; Eriksson K; Holmgren J
J Virol; 2003 Jan; 77(2):953-62. PubMed ID: 12502811
[TBL] [Abstract][Full Text] [Related]
10. CpG oligodeoxynucleotide augments HSV-2 glycoprotein D DNA vaccine efficacy to generate T helper 1 response and subsequent protection against primary genital herpes infection in mice.
Tengvall S; Josefsson A; Holmgren J; Harandi AM
J Reprod Immunol; 2005 Dec; 68(1-2):53-69. PubMed ID: 16229896
[TBL] [Abstract][Full Text] [Related]
11. Effects of the estrous cycle on local humoral immune responses and protection of intranasally immunized female mice against herpes simplex virus type 2 infection in the genital tract.
Gallichan WS; Rosenthal KL
Virology; 1996 Oct; 224(2):487-97. PubMed ID: 8874509
[TBL] [Abstract][Full Text] [Related]
12. Protection against genital herpes infection in mice immunized under different hormonal conditions correlates with induction of vagina-associated lymphoid tissue.
Gillgrass AE; Tang VA; Towarnicki KM; Rosenthal KL; Kaushic C
J Virol; 2005 Mar; 79(5):3117-26. PubMed ID: 15709031
[TBL] [Abstract][Full Text] [Related]
13. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.
Jiang JQ; Patrick A; Moss RB; Rosenthal KL
J Virol; 2005 Jan; 79(1):393-400. PubMed ID: 15596832
[TBL] [Abstract][Full Text] [Related]
14. A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2.
Parr MB; Kepple L; McDermott MR; Drew MD; Bozzola JJ; Parr EL
Lab Invest; 1994 Mar; 70(3):369-80. PubMed ID: 8145530
[TBL] [Abstract][Full Text] [Related]
15. The potential of immunostimulatory CpG DNA for inducing immunity against genital herpes: opportunities and challenges.
Harandi AM
J Clin Virol; 2004 Jul; 30(3):207-10. PubMed ID: 15135735
[TBL] [Abstract][Full Text] [Related]
16. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge.
Dumais N; Patrick A; Moss RB; Davis HL; Rosenthal KL
J Infect Dis; 2002 Oct; 186(8):1098-105. PubMed ID: 12355360
[TBL] [Abstract][Full Text] [Related]
17. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2.
Milligan GN; Bernstein DI; Bourne N
J Immunol; 1998 Jun; 160(12):6093-100. PubMed ID: 9637526
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of genital T cell responses to herpes simplex virus type 2 resulting from immunization of the nasal mucosa.
Milligan GN; Dudley-McClain KL; Chu CF; Young CG
Virology; 2004 Jan; 318(2):507-15. PubMed ID: 14972519
[TBL] [Abstract][Full Text] [Related]
19. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
de Jong S; Chikh G; Sekirov L; Raney S; Semple S; Klimuk S; Yuan N; Hope M; Cullis P; Tam Y
Cancer Immunol Immunother; 2007 Aug; 56(8):1251-64. PubMed ID: 17242927
[TBL] [Abstract][Full Text] [Related]
20. Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes.
Tengvall S; Lundqvist A; Eisenberg RJ; Cohen GH; Harandi AM
J Virol; 2006 Jun; 80(11):5283-91. PubMed ID: 16699008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
